Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHI NASDAQ:CWBR NYSE:OGEN NASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.39-2.0%$1.65$1.20▼$3.35$4.54M0.87104,880 shs15,246 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AOGENOragenics$1.03-7.9%$1.58$1.03▼$38.70$4.25M0.65318,914 shs119,318 shsONCOOnconetix$2.93-2.3%$3.67$2.61▼$552.50$4.64M3.37137,925 shs19,886 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma-0.93%-6.71%-19.13%-13.06%-93.01%CWBRCohBar0.00%0.00%0.00%0.00%-4.65%OGENOragenics-7.90%-7.21%-20.16%-71.39%-96.85%ONCOOnconetix-2.33%-1.35%-8.72%-53.36%-99.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHIChina PharmaN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenics0.1399 of 5 stars0.04.00.00.00.60.00.0ONCOOnconetix1.0892 of 5 stars0.04.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.40M1.03N/AN/A$0.70 per share1.99CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/AONCOOnconetix$2.52M1.80N/AN/A$3.82 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AOGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/AONCOOnconetix-$58.69MN/A0.00∞N/A-3,327.03%-192.74%-89.55%N/ALatest CWBR, ONCO, OGEN, and CPHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ONCOOnconetixN/A-$4.05N/A-$4.76N/A$0.11 million6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26CWBRCohBarN/AN/AN/AOGENOragenicsN/A1.931.93ONCOOnconetixN/A0.070.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/ACWBRCohBar2.47%OGENOragenics18.71%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma17.32%CWBRCohBar6.51%OGENOragenics4.90%ONCOOnconetix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableCWBRCohBar102.91 millionN/ANot OptionableOGENOragenics54.13 million10.98 millionN/AONCOOnconetix121.55 million1.50 millionN/ACWBR, ONCO, OGEN, and CPHI HeadlinesRecent News About These CompaniesOnconetix Director Resignation Amid Financial AdjustmentsAugust 12, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)July 17, 2025 | globenewswire.comOnconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | finanznachrichten.deOnconetix Shares Touch All-Time Low on Reverse Merger With OcuvexJuly 16, 2025 | marketwatch.comONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to ShareholdersJuly 16, 2025 | businesswire.comOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | globenewswire.comOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11, 2025 | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comOnco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision OncologyMay 22, 2025 | accessnewswire.comAOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqMay 22, 2025 | globenewswire.comOnco-Innovations Uplists to Cboe CanadaMay 22, 2025 | businesswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comAOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comAOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging By Nathan Reiff | August 4, 2025CWBR, ONCO, OGEN, and CPHI Company DescriptionsChina Pharma NYSE:CPHI$1.39 -0.03 (-2.04%) Closing price 08/29/2025 03:55 PM EasternExtended Trading$1.38 -0.01 (-0.43%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.CohBar NASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Oragenics NYSE:OGEN$1.03 -0.09 (-7.90%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$1.06 +0.03 (+3.40%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Onconetix NASDAQ:ONCO$2.93 -0.07 (-2.33%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.98 +0.04 (+1.54%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
